Preparation and characterization of microemulsion formulations of nicotinic acid and its prodrugs for transdermal delivery

Pharmaceutical Development and Technology

Volumn 18, Issue 4, 2013, Pages 834-843

  Tashtoush, Bassam M ^a   Bennamani, Amina N ^a   Al Taani, Bashar M ^a  

^a JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

Author keywords

Dodecyl nicotinate; Microemulsion; Myristyl nicotinate; Nicotinic acid; Transdermal delivery

Indexed keywords

DODECYL NICOTINATE; LABRASOL; MYRISTIC ACID ISOPROPYL ESTER; MYRISTYL NICOTINATE; NICOTINIC ACID; NICOTINIC ACID DERIVATIVE; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION (PARAMETERS); CONDUCTANCE; CONTROLLED STUDY; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG STABILITY; IN VITRO STUDY; LIPOPHILICITY; LIQUID CHROMATOGRAPHY; LIVER METABOLISM; MALE; MICROEMULSION; MOUSE; NONHUMAN; PARTICLE SIZE; PH; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REFRACTION INDEX; SKIN ABSORPTION; VASODILATATION; VISCOSITY;

ADMINISTRATION, CUTANEOUS; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIFFUSION; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; EMULSIONS; EXCIPIENTS; HYDROGEN-ION CONCENTRATION; MALE; MICE; NIACIN; NICOTINIC ACIDS; PARTICLE SIZE; PHASE TRANSITION; PRODRUGS; SKIN ABSORPTION; VISCOSITY;

EID: 84877850297     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2012.727003     Document Type: Article

References (42)

1. Said HM, Nabokina SM, Balamurugan K, Mohammed ZM, Urbina C, Kashyap ML. Mechanism of nicotinic acid transport in human liver cells: Experiments with HepG2 cells and primary hepatocytes. Am J Physiol, Cell Physiol 2007;293:C1773-C1778.
2. Durrer A, Walther B, Racciatti A, Boss G, Testa B. Structuremetabolism relationships in the hydrolysis of nicotinate esters by rat liver and brain subcellular fractions. Pharm Res 1991;8:832-839.
3. Grundy SM, Mok HY, Zech L, Berman M. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res 1981;22:24-36.
4. Vaccari CS, Hammoud RA, Nagamia SH, Ramasamy K, Dollar AL, Khan BV. Revisiting niacin: Reviewing the evidence. J Clin Lipidol 2007;1:248-255.
5. Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 2003;9:352-355.
6. Drug Information Provided by Lexi-Comp. Niacin The Merck Manuals Online Medical Library 2009.
7. Maccubbin D, Koren MJ, Davidson M, Gavish D, Pasternak RC, Macdonell G et al. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extendedrelease in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol 2009;104:74-81.
8. Jacobson EL, Jacobson MK, Kim H, Kim M, Qasem JG. Topical formulations for the transdermal delivery of niacin and methods of treating hyperlipidemia. US Patent 6677361. 2004.
9. Opinion of the Scientific Committee on Food on the Tolerable Upper Intake Levels of Nicotinic Acid and Nicotinamide (Niacin). Scientific committee on food SCF/CS/NUT/UPPLEV/39 Final. 2002:1-20.
10. Kane MP, Hamilton RA, Addesse E, Busch RS, Bakst G. Cholesterol and glycemic effects of Niaspan in patients with type 2 diabetes. Pharmacotherapy 2001;21:1473-1478.
11. Pieper JA. Overview of niacin formulations: Differences in pharmacokinetics, efficacy, and safety. Am J Health Syst Pharm 2003;60:S9-14; quiz S25.
12. Pieper JA. Understanding niacin formulations. Am J Manag Care 2002;8:S308-S314.
13. National Drugs and Poisons Schedule Committee. Record of Reasons of Meeting 53. June 2008;206-207.
14. University of Arizona: Southwest Environmental Health Sciences Center. Available at: http://swehsc.pharmacy.arizona.edu. Accessed on: March 2010.
15. Weiner M. Clinical pharmacology and pharmacokinetics of nicotinic acid. Drug Metab Rev 1979;9:99-106.
16. Jacobson EL, Kim H, Kim M, Wondrak GT, Jacobson MK. (2008). Developing topical prodrugs for skin cancer prevention. In: Alberts DS, Hess LM, eds. Fundamentals of Cancer Prevention. Verlag Berlin Heidelberg: Springer, 215-237.
17. Catz P, Shinn W, Kapetanovic IM, Kim H, Kim M, Jacobson EL et al. Simultaneous determination of myristyl nicotinate, nicotinic acid, and nicotinamide in rabbit plasma by liquid chromatographytandem mass spectrometry using methyl ethyl ketone as a deproteinization solvent. J Chromatogr B Analyt Technol Biomed Life Sci 2005;829:123-135.
18. Badgett CO, Provost RC, Ogg CL, Woodward CF. Nicotinic acid. Water-insoluble esters and amides. J Am Chem Soc 1945;67:1135-1138.
19. Kogan A, Garti N. Microemulsions as transdermal drug delivery vehicles. Adv Colloid Interface Sci 2006;123-126:369-385.
20. Kaur IP, Kapila M, Agrawal R. Role of novel delivery systems in developing topical antioxidants as therapeutics to combat photoageing. Ageing Res Rev 2007;6:271-288.
21. Heuschkel S, Goebel A, Neubert RH. Microemulsions-modern colloidal carrier for dermal and transdermal drug delivery. J Pharm Sci 2008;97:603-631.
22. Pappinen S, Urtti A. (2006). Microemulsions in topical drug delivery. In: Smith EW, Maibach HI, eds. Percutaneous Penetration Enhancers. 2nd edition. Boca Raton: CRC Press, Taylor & Francis Group, 109-116.
23. Djordjevic L, Primorac M, Stupar M. In vitro release of diclofenac diethylamine from caprylocaproyl macrogolglycerides based microemulsions. Int J Pharm 2005;296:73-79.
24. Peira E, Carlotti ME, Trotta C, Cavalli R, Trotta M. Positively charged microemulsions for topical application. Int J Pharm 2008;346:119-123.
25. Kristl J, Volk B, Gasperlin M, Sentjurc M, Jurkovic P. Effect of colloidal carriers on ascorbyl palmitate stability. Eur J Pharm Sci 2003;19:181-189.
26. Kreilgaard M. Influence of microemulsions on cutaneous drug delivery. Adv Drug Deliv Rev 2002;54 Suppl 1:S77-S98.
27. Djekic L, Primorac M. The influence of cosurfactants and oils on the formation of pharmaceutical microemulsions based on PEG-8 caprylic/capric glycerides. Int J Pharm 2008;352:231-239.
28. Walters KA, Brain KR. (2002). Dermatological formulation and transdermal systems. In: Walters KA, ed. Dermatological and Transdermal Formulations. New York: Marcel Dekker Inc, 349-432.
29. Teichmann A, Heuschkel S, Jacobi U, Presse G, Neubert RH, Sterry W et al. Comparison of stratum corneum penetration and localization of a lipophilic model drug applied in an o/w microemulsion and an amphiphilic cream. Eur J Pharm Biopharm 2007;67:699-706.
30. Yuan Y, Li SM, Mo FK, Zhong DF. Investigation of microemulsion system for transdermal delivery of meloxicam. Int J Pharm 2006;321:117-123.
31. Subramanian N, Ghosal SK, Acharya A, Moulik SP. Formulation and physicochemical characterization of microemulsion system using isopropyl myristate, medium-chain glyceride, polysorbate 80 and water. Chem Pharm Bull 2005;53:1530-1535.
32. Fanun M. A study of the properties of mixed nonionic surfactants microemulsions by NMR, SAXS, viscosity and conductivity. J Mol Liq 2008;142:103-110.
33. Kim BY, Doh HJ, Le TN, Cho WJ, Yong CS, Choi HG et al. Ketorolac amide prodrugs for transdermal delivery: Stability and in vitro rat skin permeation studies. Int J Pharm 2005;293:193-202.
34. Muller B, Kasper M, Surber C, Imanidis G. Permeation, metabolism and site of action concentration of nicotinic acid derivatives in human skin. Correlation with topical pharmacological effect. Eur J Pharm Sci 2003;20:181-195.
35. Abraham MH, Acree WE Jr. Characterisation of the water-isopropyl myristate system. Int J Pharm 2005;294:121-128.
36. Stinchcomb AL, Paliwal A, Dua R, Imoto H, Woodard RW, Flynn GL. Permeation of buprenorphine and its 3-alkyl-ester prodrugs through human skin. Pharm Res 1996;13:1519-1523.
37. Sinha VR, Kaur MP. Permeation enhancers for transdermal drug delivery. Drug Dev Ind Pharm 2000;26:1131-1140.
38. Pathan IB, Setty CM. Chemical penetration enhancers for transdermal drug delivery systems. Trop J Pharmaceut Res 2009;8:173-179.
39. Santos P, Watkinson AC, Hadgraft J, Lane ME. Application of microemulsions in dermal and transdermal drug delivery. Skin Pharmacol Physiol 2008;21:246-259.
40. Davis AF, Gyuric RJ, Hadgraft J, Pellet MA, Walters KA. (2002). Formulation strategies for modulating skin permeation. In: Walters KA, ed. Dermatological and Transdermal Formulations. New York: Marcel Dekker Inc, 271-318.
41. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev 2004;56:603-618.
42. Funke AP, Schiller R, Motzkus HW, Gunther C, Muller RH, Lipp R. Transdermal delivery of highly lipophilic drugs: In vitro fluxes of antiestrogens, permeation enhancers, and solvents from liquid formulations. Pharm Res 2002;19:661-668.